[go: up one dir, main page]

AR061368A1 - 3- cianopiridinas sustituidas como inhibidores de la proteina quinasa - Google Patents

3- cianopiridinas sustituidas como inhibidores de la proteina quinasa

Info

Publication number
AR061368A1
AR061368A1 ARP070102593A ARP070102593A AR061368A1 AR 061368 A1 AR061368 A1 AR 061368A1 AR P070102593 A ARP070102593 A AR P070102593A AR P070102593 A ARP070102593 A AR P070102593A AR 061368 A1 AR061368 A1 AR 061368A1
Authority
AR
Argentina
Prior art keywords
alkyl
haloalkyl
alkynyl
alkenyl
aryl
Prior art date
Application number
ARP070102593A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR061368A1 publication Critical patent/AR061368A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)

Abstract

La presente proporciona compuestos de 3-cianopiridinas sustituidas y una composicion farmacéutica en base al compuesto de formula (1), los compuestos de la presente son utiles para tratar enfermedades autoinmunes e inflamatorias mediante la administracion de una cantidad terapéuticamente efectiva del compuesto. Reivindicacion 1: Un compuesto de formula 1 o de formula 2 o una sal, hidrato, o éster farmacéuticamente aceptable del mismo, donde: X se selecciona entre a) -NR3-Y-, b) -O-Y-, c) -S(O)m-Y-, d) -S(O)mNR3-Y-, e) -NR3S(O)m-Y-, f) -C(O)NR3-Y-, g) -C(S)NR3-Y-, h) -NR3C(O)-Y-, i) -NR3C(S)-Y-, j) -C(O)O-Y-, k) -OC(O)-Y-, y l) un enlace covalente; Y, en cada caso, se selecciona independientemente entre a) alquilo C1-10 divalente, b) alquenilo C2-10 divalente, c) alquinilo C2-10 divalente, d) haloalquilo C1-10 divalente, y e) un enlace covalente; R1 se selecciona entre a) alquiloo C1-10, b) cicloalquilo C3-14, c) cicloheteroalquilo de 3 a14 miembros, d) arilo C8-14 policíclico y e)heteroarilo de 5 a 14 miembros, donde cada grupo está opcionalmente sustituido con 1 a 4 R4; R2 es arilo C6-14 o un grupo heteroarilo de 5-14 miembros, donde cada grupo está opcionalmente sustituido con 1 a 4 grupos seleccionados independientemente entre -Y-R4 u -O-Y-R4; R3 se selecciona entre a) H, b) alquilo C1-10, c) alquenilo C2-10, d) alquinilo C2-10, y e) haloalquilo C1-10, R4 en cada caso, se selecciona independientemente entre a) halogeno, b) -CN, c) -NO2, d) oxo, e) -O-Y-R5, f) -NR6-Y-R7, g) -N(O)R6-Y-R7, h) -S(O)m-Y-R5, i) -S(O)mO-Y-R5, j) -S(O)mNR6-Y-R7, k) -C(O)-Y-R5, l) -C(O)O-Y-R5, m) -C(O)NR6-Y-R7, n) -C(S)NR6-Y-R7, o) alquilo C1-10, p) alquenilo C2-10, q) alquinilo C2-10, r) haloalquilo C1-10, s) cicloalquilo C3-14, t) arilo C6-14, u) cicloheteroalquilo de 3-14 miembros, y v) heteroarilo de 5-14 miembros, donde cada uno de o) hasta v) está opcionalmente sustituido con 1 a 4 grupos -Y-R8; R5, en cada caso, se selecciona independientemente entre a) H, b) -C(O)R9, c) -C(O)OR9, d) alquilo C1-10, e) alquenilo C2-10, f) alquinilo C2-10, g) haloalquilo C1-10, h) cicloalquilo C3-10, i) arilo C6-14, j) cicloheteroalquilo de 3 a 14 miembros, y k) heteroarilo de 5 a 14 miembros, donde cada uno de d) hasta k) está opcionalmente sustituido con 1 a 4 grupos -Y-R8; R6 y R7, en cada caso, se seleccionan independientemente entre a) H, b) -O-Y-R9, c) S(O)m-Y-R9, d) -S(O)mO-Y-R9, e) -C(O)-Y-R9, f) -C(O)-Y-R9, g) -C(O)NR10-Y-R11, h) -C(S)NR10-Y- R11, i) alquilo C1-10, j) alquenilo C2-10, k) alquinilo C2-10, l) haloalquilo C1-10, m) cicloalquilo C3-14, n) arilo C6-14, o) cicloheteroalquilo de 3 a 14 miembros, y p) heteroarilo de 5 a 14 miembros; donde cada uno de i) hasta p) está opcionalmente sustituido con 1 a 4 grupos -Y-R8; R8 en cada caso, se selecciona independientemente entre a) halogeno, b) -CN, c) -NO2, d) oxo, e) -O-Y-R9, f) -NR10-Y-R11, g) -N(O)R10-Y-R11, h) -S(O)m-Y-R9, i) S(O)mO-Y-R9, j) -S(O)mNR10-Y-R11, k) - C(O)-Y-R9, l) -C(O)O-Y-R9, m) -C(O)NR10-Y-R11, n) -C(S)NR10-Y-R11, o) alquilo C1-10, p) alquenilo C2-10, q) alquinilo C2-10, r) haloalquilo C1-10, s) cicloalquilo C3-14, t) arilo C6-14, u) cicloheteroalquilo de 3 a 14 miembros, y v) heteroarilo de 5 a 14 miembros, donde cada uno de o) hasta v) está opcionalmente sustituido con 1 a 4 grupos -Y-R12; R9, en cada caso, se selecciona independientemente entre a) H, b) -C(O)-alquilo C1-10, c) -C(O)OH, d) -C(O)O-aIquilo C1-10, e) alquilo C1-10, f) alquenilo C2-10, g) alquinilo C2-10, h) haloalquilo C1-10, i) cicloalquilo C3-14, j) arilo C6-14, k) cicloheteroalquilo de 3 a 14 miembros, y l) heteroarilo de 5 a 14 miembros, donde cada uno de alquilo C1-10, alquenilo C2-10, alquinilo C2-10, haloalquilo C1-10, cicloalquilo C3-14, arilo C6-14, cicloheteroalquilo de 3 a 14 miembros, y heteroarilo de 5 a 14 miembros está opcionalmente sustituido con 1 a 4 grupos R12; R10 y R11 en cada caso, se seleccionan independientemente entre a) H, b) - OH, c) -SH, d) -NH2, e) -NH-alquilo C1-10, f) N(alquilo C1-10)2, g) -S(O)m- alquilo C1-10, h) -S(O)2OH, i) -S(O)m-Oalquilo C1-10, j) -C(O)-alquilo C1-10, k) -C(O)OH, l) -C(O)-OaIquilo C1-10, m) -C(O)NH2, n) -C(O)NH-alquilo C1-10, o) -C(O)N(alquilo C1-10)2, p) -C(S)NH2, q) -C(S)NH-alquilo C1-10, r) -C(S)N(alquilo C1-10)2, s) alquilo C1-10, t) alquenilo C2-10, u) alquinilo C2-10, v) alcoxi C1-10, w) haloalquilo C1-10, x) cicloalquilo C3-14, y) arilo C6-14, z) cicloheteroalquilo de 3 a 14 miembros, y aa) heteroarilo de 5 a 14 miembros, donde cada uno de alquilo C1-10, alquenilo C2-10, alquinilo C2-10, alcoxi C1-10, haloalquilo C1-10, cicloalquilo C3-14, arilo C6-14, cicloheteroalquilo de 3 a 14 miembros, y el heteroarilo de 5 a 14 miembros está opcionalmente sustituido con 1 a 4 grupos -Y-R12; R12, en cada caso, se selecciona independientemente entre a) halogeno, b) -CN, c) -NO2, d) oxo, e) -OH, f) -NH2, g) -NH(alquilo C1-10), h) -N(alquilo C1-10)2, l) -SH, j) -S(O)m-alquilo C1-10, k) -S(O)2OH, l) -S(O)m- Oalquilo C1-10, m) -C(O)-alquilo C1-10, n) -C(O)OH, o) -C(O)-OalquiIo C1-10, p) -C(O)NH2, q) -C(O)NH-alquilo C1-10, r) -C(O)N(alquilo C1-10)2, s) -C(S)NH2, t) -C(S)NH-alquilo C1-10, u) -C(S)N(alquilo C1-10)2, v) alquilo C1-10, w) alquenilo C2-10, x) alquinilo C2-10, y) alcoxi C1-10, z) haloalquilo C1-10, aa) cicloalquilo C3-14, ab) arilo C6-14, ac) cicloheteroalquilo de 3 a 14 miembros, y ad) heteroarilo de 5 a 14 miembros; y m es 0, 1, o 2.
ARP070102593A 2006-06-13 2007-06-13 3- cianopiridinas sustituidas como inhibidores de la proteina quinasa AR061368A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81306006P 2006-06-13 2006-06-13

Publications (1)

Publication Number Publication Date
AR061368A1 true AR061368A1 (es) 2008-08-20

Family

ID=38738795

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102593A AR061368A1 (es) 2006-06-13 2007-06-13 3- cianopiridinas sustituidas como inhibidores de la proteina quinasa

Country Status (18)

Country Link
EP (1) EP2029543B1 (es)
JP (1) JP2009539998A (es)
KR (1) KR20090018612A (es)
CN (1) CN101466678B (es)
AR (1) AR061368A1 (es)
AU (1) AU2007258237A1 (es)
BR (1) BRPI0712737A2 (es)
CA (1) CA2654515C (es)
CL (1) CL2007001737A1 (es)
ES (1) ES2558706T3 (es)
IL (1) IL194625A0 (es)
MX (1) MX2008015802A (es)
NO (1) NO20084739L (es)
PE (1) PE20080336A1 (es)
RU (1) RU2008139079A (es)
TW (1) TW200815407A (es)
WO (1) WO2007146376A2 (es)
ZA (1) ZA200810573B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2650666A1 (en) * 2006-06-13 2007-12-21 Wyeth Substituted cyanopyridines as protein kinase inhibitors
JP5584215B2 (ja) * 2008-09-02 2014-09-03 ノバルティス アーゲー ヘテロ環ｐｉｍキナーゼ阻害剤
CN113735785B (zh) * 2020-05-28 2023-10-13 南京桦冠生物技术有限公司 3,6-二氯吡嗪-2-甲腈的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1117659E (pt) * 1998-09-29 2004-04-30 Wyeth Corp Cianoquinolinas substituidas como inibidores de tirosina-quinases de proteinas
ATE370123T1 (de) * 2001-11-27 2007-09-15 Wyeth Corp 3-cyanochinoline als inhibitoren von egf-r- und her2-kinasen
MXPA05006367A (es) * 2002-12-12 2005-08-29 Pharmacia Corp Metodo de uso de compuestos de aminocianopiridina como inhibidores de cinasa-2 de proteina activada de cinasa de proteina activada por mitogeno.
JP2008540656A (ja) * 2005-05-18 2008-11-20 ワイス Ｔｐｌ２キナーゼの３−シアノキノリン阻害物質ならびにそれを製造および使用する方法

Also Published As

Publication number Publication date
CN101466678A (zh) 2009-06-24
PE20080336A1 (es) 2008-06-03
ZA200810573B (en) 2009-09-30
JP2009539998A (ja) 2009-11-19
CA2654515C (en) 2014-04-01
CA2654515A1 (en) 2007-12-21
WO2007146376A3 (en) 2008-03-13
MX2008015802A (es) 2009-01-09
AU2007258237A1 (en) 2007-12-21
KR20090018612A (ko) 2009-02-20
TW200815407A (en) 2008-04-01
WO2007146376A2 (en) 2007-12-21
CN101466678B (zh) 2012-12-26
ES2558706T3 (es) 2016-02-08
NO20084739L (no) 2009-01-06
EP2029543B1 (en) 2015-11-18
EP2029543A2 (en) 2009-03-04
CL2007001737A1 (es) 2008-01-25
IL194625A0 (en) 2009-08-03
RU2008139079A (ru) 2010-07-20
BRPI0712737A2 (pt) 2012-05-08

Similar Documents

Publication Publication Date Title
DK3041468T3 (en) CYCLIC PEPTIDOMIMETIC COMPOUNDS AS IMMUNOMODULATORS
RU2428428C2 (ru) Серусодержащие соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с
AR059425A1 (es) Amidas ciclicas condensadas del acido bencensulfonico, un metodo para su preparacion, composiciones farmaceuticas que las contienen y el empleo de las mismas en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de l-cpt1
HRP20250345T1 (hr) Konjugati antitijelo - lijek derivata cikličnih dinukleotida
AR086977A1 (es) Derivados heterociclicos nitrogenados utiles para el tratamiento del cancer y composiciones farmaceuticas que los contienen
AR066412A1 (es) Derivados de dibenzofurano y dibenzotiofeno, composiciones farmaceuticas que los contienen y usos en patologias tales como trastornos oseos, crecimiento de tumores, diabetes y obesidad.
NZ712148A (en) Wt1 antigen peptide conjugate vaccine
JO2984B1 (ar) تركيب الجسم المضاد her2
UA110259C2 (uk) Похідні піролопіримідину і пурину
RU2016130933A (ru) Сульфонамид-содержащие связывающие системы для лекарственных конъюгатов
AR039672A1 (es) Dipeptido, derivado de benzotiazepina. inhibidor del transporte ileal de acidos biliares (ibat)
AR056200A1 (es) Tieno [2,3-b]piridin-5-carbonitrilos como inhibidores de proteina quinasa
AR068057A1 (es) Esteres de 1-fenil-2-(3,5-dicloro)-piridina, metodo de preparacion de los mismos, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de enfermedades del tracto respiratorio.
AR071617A1 (es) Bencenosulfonamidas de oxazol y tiazol, composiciones farmaceuticas que las contienen, proceso de preparacion y uso de las mismas como agentes anticancerigenos.
HUE034856T2 (en) Substituted pyrrolidines as factor xia inhibitors for the treatment of thromboembolic diseases
AR077485A2 (es) Difenilureas substituidas con carboxiarilo como inhibidores de raf quinasa
AR086357A1 (es) Derivados de indazol sustituidos activos como inhibidores de quinasas
PE20061305A1 (es) Compuestos derivados de fenilacetamidas como inhibidores de proteincinasas
TW200740773A (en) Diaminopyrimidines as P2X3 and P2X2/3 modulators
ATE540037T1 (de) Triazolopyridine als phosphodiesterasehemmer zur behandlung von hautkrankheiten
MX2009005622A (es) Dihidro-imidazoles sustituidos y su uso en el tratamiento de tumores.
AR071300A1 (es) Compuestos; composiciones farmaceuticas en base al compuesto y uso del mismo para la manufactura de un medicamento
CA2968902A1 (en) Compounds derived from polymyxin
AR061368A1 (es) 3- cianopiridinas sustituidas como inhibidores de la proteina quinasa
RU2018120696A (ru) Конъюгаты анти-cd22 антитело-майтансин и способы их применения

Legal Events

Date Code Title Description
FB Suspension of granting procedure